Park Ha Biological Technology Co, LTD 20-F annual reports
The annual report filed by foreign private issuers listed on a US exchange — the 10-K’s equivalent for non-US companies.
Park Ha Biological Technology Co., Ltd. reported a substantial net loss of $24.36 million for fiscal year 2025, a significant downturn from the previous year's profit, primarily driven by increased general and administrative expenses.
Park Ha Biological Technology Co., Ltd. reported a significant net loss of $24.36 million for fiscal year 2025, driven by a surge in share-based compensation, alongside a reverse stock split to address Nasdaq's minimum bid price requirement.
Park Ha Biological Technology's annual report reveals a slight revenue decrease and ongoing risks associated with operating in the PRC, alongside efforts to strengthen internal controls.